Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this trial is to study the safety and tolerability of repeated oral doses of ELB353, to evaluate the plasma levels of ELB353 and to study their effect on substances mediating inflammation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| ELB353 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Oral, 10 days |
| |
| ELB353 |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse event frequency and intensity | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma levels of ELB353 | 1 month | |
| Inflammatory transmitter response ex vivo | 2 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antero Kallio, MD | Biotie Therapies Corp. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Biotie investigational site | Berlin | State of Berlin | 14050 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Oral, 10 days |
|